ScoreWhy is BB Biotech AG ?
1
Poor long term growth as Net Sales has grown by an annual rate of -23.70% and Operating profit at -35.39%
2
With ROE of 4.12%, it has a Very Expensive valuation with a 1.17 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 16.44%, its profits have risen by 137% ; the PEG ratio of the company is 0.2
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Finance)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-23.70%
EBIT Growth (5y)
-35.39%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0.07%
Dividend Payout Ratio
130.04%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
8.21%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.17
EV to EBIT
4.13
EV to EBITDA
4.13
EV to Capital Employed
-145.26
EV to Sales
5.08
PEG Ratio
0.21
Dividend Yield
4.62%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
4.12%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial TrendNot enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for BB Biotech AG
Net Sales - Quarterly
At CHF 16 MM has Grown at inf %
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (CHF MM)
Profit Before Tax less Other Income (PBT) - Quarterly
At CHF 261 MM has Grown at 202.64 %
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (CHF MM)
Profit After Tax (PAT) - Quarterly
At CHF 260 MM has Grown at 202.6 %
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (CHF MM)
Net Sales - Quarterly
Highest at CHF 16 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CHF MM)
Operating Profit (PBDIT) - Quarterly
Highest at CHF 261 MM.
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CHF MM)
Operating Profit Margin - Quarterly
Highest at 1,617.39%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales (CHF MM)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at CHF 261 MM.
in the last five periodsMOJO Watch
Near term PBT trend is positive
PBT less Other Income (CHF MM)
Profit After Tax (PAT) - Quarterly
Highest at CHF 260 MM.
in the last five periodsMOJO Watch
Near term PAT trend is positive
PAT (CHF MM)
Earnings per Share (EPS) - Quarterly
Highest at CHF 4.75
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (CHF)
Here's what is not working for BB Biotech AG
Dividend Payout Ratio (DPR) - Annually
Lowest at 0.00 %
in the last five yearsMOJO Watch
Company is distributing lower proportion of profits generated as dividend
DPR (%)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
